Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple mieloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multiple mieloma - antineoplastiski līdzekļi - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatas audzējiem, kastrācija-izturīgs - antineoplastiski līdzekļi - treatment of adult patients with prostate cancer.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple mieloma - antineoplastiski līdzekļi - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international n.v.    - rilpivirīna hidrohlorīds - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - edurant, kombinācijā ar citām pretretrovīrusu zālēm, norāda attieksmi pret cilvēka imūndeficīta vīrusa tipam 1 (hiv‑1) infekcijas pacientu antiretrovirālo treatment‑naïve 12 gadus veci un vecāki ar vīrusu slodzi ≤ 100000 hiv‑1 rns kopijas/ml. kā ar citiem antiretrovīrusu zālēm, genotypic pretestības pārbaude būtu ceļvedis, lietošanas edurant.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirīns - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international n.v.   - decitabine - leikēmija, mieloīds - antineoplastiski līdzekļi - pieaugušiem pacientiem ar jaunu diagnozi de novo vai sekundāru akūtu mieloīdo leikozi (aml) saskaņā ar pasaules veselības organizācijas (pvo) klasifikāciju, kuri nav standarta indukcijas ķīmijterapijas kandidāti.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international nv - paliperidone - schizophrenia; psychotic disorders - psihoterapija - invega ir norādīts ārstēšanai šizofrēnijas pieaugušajiem un pusaudžiem par 15 gadiem un vecāki. invega ir indicēts, lai ārstētu schizoaffective traucējumi pieaugušajiem.

Unione Europea - lettone - EMA (European Medicines Agency)

janssen-cilag international n.v. - paliperidona palmitāts - Šizofrēnija - psihoterapija - xeplion ir indicēts šizofrēnijas ārstēšanai pieaugušiem pacientiem, kas stabilizēti ar paliperidonu vai risperidonu. in selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.